Search

Your search keyword '"Papay, Pavol"' showing total 3 results
Start Over Author "Papay, Pavol" Database OpenAIRE
3 results on '"Papay, Pavol"'

1. sj-pdf-1-ueg-10.1177_2050640620946874 - Supplemental material for Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease

Author

Kutschera, Maximilian, Waldhör, Thomas, Gröchenig, Hans Peter, Haas, Thomas, Wenzl, Heimo, Steiner, Pius, Koch, Robert, Feichtenschlager, Thomas, Eckhardt, Gerald, Mayer, Andreas, Kirchgatterer, Andreas, Ludwiczek, Othmar, Platzer, Reingard, Papay, Pavol, Gartner, Johanna, Fuchssteiner, Harry, Paul-Gerhard Peters, Reicht, Gerhard, Moser, Gabriele, Dejaco, Clemens, Vogelsang, Harald, Primas, Christian, Novacek, Gottfried, and Miehsler, Wolfgang

Subjects
FOS: Clinical medicine, FOS: Biological sciences, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 110308 Geriatrics and Gerontology, 69999 Biological Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-1-ueg-10.1177_2050640620946874 for Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease by Maximilian Kutschera, Thomas Waldhör, Hans Peter Gröchenig, Thomas Haas, Heimo Wenzl, Pius Steiner, Robert Koch, Thomas Feichtenschlager, Gerald Eckhardt, Andreas Mayer, Andreas Kirchgatterer, Othmar Ludwiczek, Reingard Platzer, Pavol Papay, Johanna Gartner, Harry Fuchssteiner, Paul-Gerhard Peters, Gerhard Reicht, Gabriele Moser, Clemens Dejaco, Harald Vogelsang, Christian Primas, Gottfried Novacek and Wolfgang Miehsler in United European Gastroenterology Journal

Published
2020
Full Text
View/download PDF

3. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy

Author

Rahier, Jean-François, Buche, Sébastien, Peyrin-Biroulet, Laurent, Bouhnik, Yoram, Duclos, Bernard, Louis, Edouard, Papay, Pavol, Allez, Matthieu, Cosnes, Jacques, Cortot, Antoine, Laharie, David, Reimund, Jean-Marie, Lémann, Marc, Delaporte, Emmanuel, Colombel, Jean-Frédéric, Renseigné, Non, Service d'Hépato-gastroentérologie, UCL Mont Godinne, Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre de recherche biomédicale Bichat-Beaujon (CRB3), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de gastro-entérologie et assistance nutritive, Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Nephrology Service, Université de Montréal (UdeM)-Hôpital Notre-Dame de Montréal, Service de Gastro-Entérologie et Nutrition, Université Pierre et Marie Curie - Paris 6 (UPMC), Hepatogastroenterology, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de gastro-entérologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Beaujon-Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université de Montréal [Montréal]-Hôpital Notre-Dame de Montréal, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP]

Subjects
Adult, Male, Pathology, medicine.medical_specialty, Inflammatory bowel disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, medicine, Adalimumab, Humans, Immunologic Factors, Psoriasis, Crohn's disease, Hepatology, integumentary system, Tumor Necrosis Factor-alpha, business.industry, [CHIM.ORGA]Chemical Sciences/Organic chemistry, Gastroenterology, Dermatology Life Quality Index, Skin Diseases, Eczematous, Inflammatory Bowel Diseases, medicine.disease, Dermatology, Ulcerative colitis, Infliximab, 3. Good health, Anti-Tumor Necrosis Factor Therapy, Treatment Outcome, Withholding Treatment, Female, 030211 gastroenterology & hepatology, Tumor necrosis factor alpha, business, medicine.drug
Abstract

International audience; BACKGROUND & AIMS: Psoriasiform and eczematiform lesions are associated with anti-tumor necrosis factor (TNF)-α therapies. We assessed clinical characteristics, risk factors, and outcomes of skin disease in patients with inflammatory bowel diseases that presented with psoriasiform and eczematiform lesions induced by anti-TNF-α agents. METHODS: We studied 85 patients (69 with Crohn's disease, 15 with ulcerative colitis, and 1 with indeterminate colitis; 62 women) with inflammatory skin lesions (62 psoriasiform and 23 eczematiform lesions). RESULTS: Twenty-four patients had a history of inflammatory skin lesions and 15 had a familial history of inflammatory skin disease. Locations of eczematiform lesions varied whereas scalp and flexural varieties were mostly psoriasiform. Skin lesions emerged but inflammatory bowel disease was quiescent in 69 patients following treatment with any type of anti-TNF-α agent (60 with infliximab, 20 with adalimumab, and 5 with certolizumab). Topical therapy resulted in partial or total remission in 41 patients. Patients with psoriasiform lesions that were resistant to topical therapy and that changed anti-TNF-α therapies once or twice developed recurring lesions. Overall, uncontrolled skin lesions caused 29 patients to stop taking TNF-α inhibitors. CONCLUSIONS: Inflammatory skin lesions following therapy with TNF-α inhibitors occurred most frequently among women and patients with a personal or familial history of inflammatory skin disease; lesions did not correlate with intestinal disease activity. Recurring and intense skin lesions caused 34% of patients in this study to discontinue use of anti-TNF-α agents.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results